Develops mRNA medicines and vaccines using proprietary capping technology PureCap enabling Cap2 mRNA for higher protein translation, efficacy, and safety. Also provides chemically synthesized non‑IVT mRNA and cap analogs, targeting partnerships with academia, biotech‑pharma and CDMOs.